Abide Therapeutics Appoints Richard N. Kender to Board of Directors

SAN DIEGO, January (19), 2016 /PRNewswire/ — Abide Therapeutics announced today the appointment of Richard N. Kender to its Board of Directors. Kender is a consultant to biotechnology companies in the areas of partnerships and licensing and mergers and acquisitions. He was previously Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. During his career …

Abide’s Co-founders and Board Members Elected to the National Academy of Inventors

SAN DIEGO, Jan 15, 2016– Abide Therapeutics congratulates the company’s co-founders and Scientific Advisory Board members Drs. Benjamin Cravatt and Dale Boger, and Board of Directors member Dr. Paul Schimmel, on their election to the National Academy of Inventors. Election to the National Academy of Inventors recognizes exceptional contributions to the creation or facilitation of inventions that have made an …

Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer

SAN DIEGO, January 6, 2016 /PRNewswire/ — Abide Therapeutics announced today the appointment of Chan Beals, M.D., Ph.D., to the position of Chief Medical Officer. Dr. Beals has more than 15 years of experience in the pharmaceutical industry, with extensive expertise in both early and late stage clinical development. Dr. Beals was most recently Entrepreneur in Residence with Merck Research …

Abide’s ABX-1431 Modulates Endogenous Cannabinoid Tone to Treat Neuroinflammation and Neurodegeneration

SAN DIEGO, October 29, 2015 – Abide Therapeutics Developing Endocannabinoid System Modulator With Breakthrough Potential The medicinal effects of cannabinoids have been recognized for thousands of years – pain, anxiety, epilepsy, and sleep disorders are just a few of the maladies that have been treated using preparations of the Cannabis plant. More recently, researchers have engaged in identifying the pharmacologically …

Abide Therapeutics Appoints Donald Hertzog as Vice President, Early Lead Identification

SAN DIEGO, Sept. 8, 2015 /PRNewswire/ — Abide Therapeutics announced today the appointment of Donald Hertzog, Ph.D., as Vice President, Early Lead Identification. Dr. Hertzog was previously the site head and director for GlaxoSmithKline’s Molecular Discovery Research Department of Medicinal Chemistry in Research Triangle Park, North Carolina. Dr. Hertzog has more than 20 years of experience in drug discovery and development in …

Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator

SAN DIEGO, July 7, 2015 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator. ABX-1431 was discovered with Abide’s proprietary technology platform, which finds new small molecule drug candidates that target serine hydrolases, a large …

Nature Chemical Biology Recognizes Breakthrough Research Publication as one of its “Greatest Hits”

SAN DIEGO, June 4, 2015 – Breakthrough Research Formed the Foundation for Abide’s Technology Nature Chemical Biology celebrated its 10th anniversary with a special issue dedicated to the “Greatest Hits”—the best papers published by the journal to date. The 2009 paper named “Best Cartography” was authored by Abide co-founder Benjamin Cravatt, PhD, professor and chair of the Department of Chemical Physiology …

Abide Therapeutics Announces a Collaborative Agreement with the University of Oxford

SAN DIEGO, November 4, 2014 /PRNewswire/ — Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets. Under the three-year agreement, Abide …

Abide in the Top 10 of Life Science Startups to Watch in the US

SAN DIEGO, October 27, 2014 – Abide was recognized as #9 on BioSpace’s list of Top 30 Life Science Startups to Watch in the U.S. The list was ranked cumulatively based on points awarded in five categories: finance, collaborations, pipeline, sales, and editorial. 9. Abide Therapeutics Points: 17 Founded: 2011 Location: San Diego, Calif. Notable: – In 2013, Abide entered …

Abide Therapeutics Appoints Nancy Thornberry to Board of Directors

SAN DIEGO, July 29, 2014 /PRNewswire/ — Abide Therapeutics announced today the appointment of Nancy Thornberry to its board of directors. Thornberry was previously senior vice president and franchise head, Diabetes and Endocrinology for Merck & Co. Inc., where she led discovery, clinical research, strategy and overall pipeline management in diabetes, osteoporosis, fertility and contraception. Thornberry, a distinguished pharmaceutical scientist, …